Noninvasive Hemoglobin Measurement Reduce Invasive Procedures in Thalassemia Patients

Simple item page
dc.contributor.authorBıcılıoğlu Y.
dc.contributor.authorBal A.
dc.contributor.authorDemir Yenigürbüz F.
dc.contributor.authorErgonul E.
dc.contributor.authorGeter S.
dc.contributor.authorKazanasmaz H.
dc.contributor.authorBal U.
dc.date.accessioned2024-07-22T08:05:00Z
dc.date.available2024-07-22T08:05:00Z
dc.date.issued2022
dc.description.abstractThis study was conducted to investigate the agreement between laboratory hemoglobin (LabHb) measured in venous blood and noninvasive, spectrophotometric hemoglobin (SpHb) measurement and the usability of SpHb measurement in the transfusion decision-making in patients with thalassemia whose hemoglobin (Hb) was monitored by taking blood samples at frequent intervals and who were transfused. Cardiac pulse, oxygen saturation, Pleth variability index (PVI), and SpHb values were measured in patients who came to the hematology outpatient clinic for a control visit and whose Hb levels were planned to be measured. Venous blood samples were taken for LabHb measurement, which we accept as the gold standard. Cohen’s kappa value was calculated for the agreement between SpHb measurements and LabHb values. The relationship and predictability between both measurement methods were evaluated by Pearson correlation analysis, a modified Bland-Altman plot and the linear regression model. In the study conducted with a total of 110 children with thalassemia, a moderate level of agreement between the two measurement methods (kappa = 0.370, p < 0.0001) and a significantly high correlation between the two tests (r = 0.675) were found. The mean bias between the differences was found to be 0.3 g/dL (–1.27 to 1.86 g/dL). The sensitivity and the specificity of SpHb in identifying patients who needed transfusions (Hb <10.0 g/dL) were calculated as 92.2 and 57.1%, respectively. Our results suggest SpHb measurement may be used to screen anemia in hemodynamically stable hemoglobinopathy patients and even for transfusion decision-making with combination clinical findings. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.DOI-ID10.1080/03630269.2022.2078726
dc.identifier.issn03630269
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12944
dc.language.isoEnglish
dc.publisherTaylor and Francis Ltd.
dc.subjectChild
dc.subjectHemoglobinometry
dc.subjectHemoglobins
dc.subjectHumans
dc.subjectOximetry
dc.subjectProspective Studies
dc.subjectThalassemia
dc.subjecthemoglobin
dc.subjecthemoglobin
dc.subjectArticle
dc.subjectbeta thalassemia
dc.subjectblood sampling
dc.subjectchild
dc.subjectclinical decision making
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjecterythrocyte transfusion
dc.subjectfemale
dc.subjectgold standard
dc.subjecthuman
dc.subjectinvasive procedure
dc.subjectlaboratory test
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectnon invasive measurement
dc.subjectoutpatient department
dc.subjectoxygen saturation
dc.subjectpediatric patient
dc.subjectschool child
dc.subjectsensitivity and specificity
dc.subjectspectrophotometry
dc.subjectthalassemia intermedia
dc.subjectthalassemia major
dc.subjecttransfusion dependent thalassemia
dc.subjectusability
dc.subjectvenous blood
dc.subjecthemoglobin determination
dc.subjectoximetry
dc.subjectprospective study
dc.subjectthalassemia
dc.titleNoninvasive Hemoglobin Measurement Reduce Invasive Procedures in Thalassemia Patients
dc.typeArticle

Files

Collections

Scopus Koleksiyonu